Abstract
Background: The SARS-CoV-2 coronavirus is a new type of coronavirus that can affect people and the disease it causes is called COVID-19. Coronaviruses are enveloped RNA viruses that cause respiratory illnesses of varying severity, from the common cold to deadly pneumonia. The WHO first learned of the existence of this new virus on December 31, 2019, when it was informed of a group of cases of "viral pneumonia" that had been declared in Wuhan. Methodology: A narrative review was carried out through various databases from January 2020 to June 2021; the search and selection of articles was carried out in journals indexed in English. The following keywords were used: Coronavirus, Sars-Cov 2, Covid 19, ARDS in Covid 19, Antibiotics Associated with Sars-Cov 2 Results: There are no controlled clinical trials evaluating the use of empirical antimicrobials in patients with COVID-19 or other coronaviruses. Therefore, the recommendations are based on extrapolation of data from other viral pneumonias that may suffer from bacterial superinfection, particularly viral pneumonias due to influenza. Conclusions: The present review seeks to clarify the functional role that antimicrobials have with respect to infection by sars-cov 2 (COVID-19), in which circumstances they are necessary to use them and which do not merit it.
Highlights
Numerous coronaviruses, discovered in domestic poultry in the 1930s, cause respiratory, gastrointestinal, liver and neurological diseases in animals
Three of the 7 coronaviruses cause much more severe and sometimes fatal respiratory infections in humans than the other coronaviruses and have caused major outbreaks of deadly pneumonia in the 21st century: severe acute respiratory syndrome (SARS)-CoV-2 is a new coronavirus identified as the cause of the 2019 coronavirus disease (COVID-19) that began in Corresponding Author: Carlos Mauricio Vergara Lob
50 original and review publications related to the subject studied were identified, of which 20 articles met the specified inclusion requirements, such as, articles that were in a range not less than the year 2020, that were full-text articles and that reported on the use of antibiotics in patients infected with sars-cov 2
Summary
Numerous coronaviruses, discovered in domestic poultry in the 1930s, cause respiratory, gastrointestinal, liver and neurological diseases in animals. 4 out of 7 coronaviruses cause symptoms of the common cold. Coronaviruses 229E, OC43, NL63, and HKU1 cause about 15-30% of common cold cases. Three of the 7 coronaviruses cause much more severe and sometimes fatal respiratory infections in humans than the other coronaviruses and have caused major outbreaks of deadly pneumonia in the 21st century: SARS-CoV-2 is a new coronavirus identified as the cause of the 2019 coronavirus disease (COVID-19) that began in Corresponding Author: Carlos Mauricio Vergara Lob. The SARS-CoV-2 coronavirus is a new type of coronavirus that can affect people and the disease it causes is called COVID-19. Coronaviruses are enveloped RNA viruses that cause respiratory illnesses of varying severity, from the common cold to deadly pneumonia. Conclusions: The present review seeks to clarify the functional role that antimicrobials have with respect to infection by sars-cov 2 (COVID-19), in which circumstances they are necessary to use them and which do not merit it
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmaceutical and Bio-Medical Science
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
